Cell-free DNA sequencing

01Overview and value chain#

Markers EC: EU IVDR 2017/746 companion-diagnostic framework + FDA/EMA oncology CDx pathways | OECD: Biotech & health | Regulator: FDA (USA), EMA (EU), NMPA (China)

Cell-free DNA sequencing reads the small fragments of DNA that dying cells shed into the bloodstream, turning a blood draw into a molecular sample of the tumors, the placenta or the transplant that shed them. The technology stacks three hard problems: recovering short (~140–170 bp) fragments at parts-per-thousand concentration against a vast wild-type background; building libraries from picogram inputs without letting preparation errors masquerade as variants; and suppressing sequencing noise with molecular barcodes and unique-molecule counting so that a signal hiding at one-in-a-million frequency survives the read. What began as prenatal trisomy screening has become three markets in one — non-invasive prenatal testing, minimal-residual-disease surveillance after treatment, and therapy-selection liquid biopsy — and each new market pushes the limit of detection another order of magnitude deeper. The regulatory record in the corpus shows how far that has gone: one vendor holds EU IVDR Class C certification across multiple cancers while another holds the first FDA approval for a liquid biopsy in non-small-cell lung cancer, and both run laboratory networks at clinical-throughput scale.

Key directions of cell-free DNA sequencing:

1. Minimal-residual-disease surveillance (MRD Monitoring): tumor-informed and tumor-naive panels tracking recurrence months before imaging; Natera’s Signatera holds EU IVDR Class C certification across multiple cancers plus FDA companion-diagnostic approval in muscle-invasive bladder cancer and a PMDA approval in Japan for colorectal cancer.
2. Therapy-selection liquid biopsy (Therapy Selection): comprehensive genomic profiling from plasma — Guardant Health’s Guardant360 CDx has been FDA-approved since 2020, with a May 2026 approval for the Liquid CDx generation.
3. Multi-cancer screening (Early Detection): blood tests that look for signal before symptoms — Guardant’s Shield test received FDA clearance in 2024 as the screening frontier of the cfDNA market.
4. Prenatal and donor-derived sampling (NIPT and Beyond): the original application — counting chromosome-scale aneuploidy from placental cfDNA — remains the volume base of the sequencing pipeline.

Sectoral value chain#

[blood draw] ──> [plasma separation] ──> [cfDNA extraction]
                                               │
                                     (picogram library input)
                                               ▼
[clinical report] <── [variant calling/reporting] <── [error-corrected sequencing]

Value chain levels#

Cross-cutting technologies of the sector:

• Molecular barcoding (UMI Error Correction): unique molecular identifiers that let the pipeline separate true variants from sequencing noise.
• Tumor-informed panel design (Patient-Specific Panels): bespoke assays built from each patient’s tumor genotype for maximal MRD sensitivity.
• Companion-diagnostic regulatory chains (CDx Co-approvals): drug–diagnostic co-approval packages that tie cfDNA assays to specific therapies.

02US#

The US is both the technology center and the reimbursement battleground — FDA approvals and Medicare coverage decisions set the pace for the whole field.

First FDA liquid-biopsy approvals, MRD guideline traction, national lab networks#

• Guardant360 approvals: FDA approval of Guardant360 CDx in 2020 as the blood-based companion diagnostic for non-small-cell lung cancer, the Liquid CDx generation in May 2026, and the Shield screening test in 2024.
• Signatera’s regulatory stack: FDA companion-diagnostic approval in muscle-invasive bladder cancer, EU IVDR Class C certification across multiple cancers, and a PMDA approval in Japan — one assay carrying three regulatories.
• Clinical laboratory scale: Natera’s Austin expansion is designed to create the world’s largest sequencing capacity and up to 400 new jobs, on top of laboratories in Austin, San Carlos and Boulder (Colorado).

03CN#

China runs a parallel cfDNA market at national scale, with NMPA pathways for prenatal screening and oncology panels and home-grown sequencing champions — the corpus’s dossier coverage there is still ledger-thin, so this section carries market structure rather than vendor claims.

NMPA oncology panels, prenatal screening volume, domestic sequencing platforms#

• NMPA tumor-panel pathway: Chinese liquid-biopsy panels clear the NMPA route separately from prenatal licenses, and oncology NGS leaders are submitting early-screening panels for colorectal cancer.
• Prenatal screening at population scale: NIPT volume made China one of the largest cfDNA markets by draw count before oncology arrived.
• Domestic platforms: Chinese sequencers supply the domestic cfDNA pipeline, decoupling it from US instrument exports.

04EU#

Europe’s role is the IVDR: the 2017/746 regulation’s Class C requirements are the strictest evidentiary bar the sector faces, and the certifications now appearing against it are the market passports.

IVDR Class C certification, pharmacopoeial-era quality, PMDA-EU reciprocity#

• Signatera under IVDR: EU Class C certification across multiple cancer types — the first corpus-grounded example of an MRD assay clearing Europe’s post-2022 device regime.
• Laboratory licensure map: CLIA and CAP accreditation plus state licensure in New York and California shape US throughput, while European labs face national accreditation under the same ISO 15189 spine.
• Japan as reciprocal market: PMDA approval for Signatera in colorectal cancer shows the MRD regulatory template already replicating beyond the US-EU axis.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack is a noise war: every stage exists to keep preparation and sequencing errors from impersonating biology.

1. Stabilized collection and extraction (Blood-to-Library Front End):
   • cfDNA-stabilizing tubes hold the fragment landscape for days, protecting the ~140–170 bp tumor-derived fraction from dilution by genomic DNA.
   • case: high-throughput extraction feeding Natera’s Austin expansion — designed to be the world’s largest sequencing capacity.
2. Molecular-barcoded libraries (UMI Counting):
   • unique molecular identifiers tag each original fragment, so consensus collapsing can distinguish a one-in-a-million variant from a sequencing error.
   • case: tumor-informed Signatera panels tracking recurrence across multiple cancers under IVDR Class C certification.
3. Multi-cancer and screening assays (Population-Scale cfDNA):
   • screening moves the technology from patients to populations, demanding specificity at population scale.
   • case: Guardant’s Shield blood test, FDA-cleared in 2024, with laboratory capacity investment accelerating through 2026 to match volume.

07Value chains and production pipelines#

Industrial pipeline of a cfDNA clinical laboratory (CLIA / CAP / IVDR regime)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Stabilized blood draw  │ ───> │ 2. Plasma separation      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Error-corrected seq.   │ <─── │ 3. Extraction + library   │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Variant calling        │ ───> │ 6. Clinical report, CDx   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Stabilized blood draw

Blood is drawn into cfDNA-preserving tubes, fixing the fragment landscape against cell lysis during transport to the laboratory.

Stage 2: Plasma separation

Double centrifugation within the stability window separates plasma from cells, because a single lysed leukocyte can swamp a tumor’s cfDNA signal.

Stage 3: Extraction and library preparation

Short-fragment-optimized purification recovers picogram cfDNA, and adapters with molecular barcodes convert it into pooled, indexed libraries.

Stage 4: Error-corrected sequencing

Deep sequencing runs with unique-molecule counting; consensus rules push the reliable detection threshold down to allele fractions ordinary panels cannot see.

Stage 5: Variant calling

Bioinformatics pipelines apply tumor-informed or tumor-naive models, converting counted molecules into recurrence, screening or therapy-selection calls.

Stage 6: Clinical reporting

Boarded interpretation links calls to therapy decisions under the CLIA/CAP/IVDR regime, closing the loop from blood draw to treatment choice.